Loading...

Purified anti-mouse Ly-6G Antibody

Pricing & Availability
Clone
1A8 (See other available formats)
Regulatory Status
RUO
Other Names
Lymphocyte antigen 6 complex, locus G
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1-1A8_Pure_061708.jpg
C57BL/6 bone marrow cells stained with 1A8 purified, followed by anti-rat IgG PE (myeloid cells were gated for analysis)
  • 1-1A8_Pure_061708.jpg
    C57BL/6 bone marrow cells stained with 1A8 purified, followed by anti-rat IgG PE (myeloid cells were gated for analysis)
  • 2-1A8_Purified_Ly-6G_Antibody_IHC_102518
    Fresh, frozen mouse spleen was stained with purified Ly6G clone 1A8 conjugated and detected with a Cy5 CODEX™ oligonucleotide duplex (red). Samples were counterstained with TCR FITC (green). Data generated at Akoya Biosciences, Inc. using the CODEX™ technology.
  • 3-1A8_Purified_Ly-6G_Antibody_IHC_022013
    Mouse uterine tissue fixed in 10% formalin, paraffin embedded, and sliced to 4 µm. After deparaffination and antigen retrieval, sample was stained using an automatic slide stainer. The anti-mouse Ly6G primary antibody was applied at 1:500 dilution in blocking buffer for 1 hr at RT and DAB was used for visualization.
Compare all formats
Cat # Size Price Save
127601 50 µg ¥11,570
127602 500 µg ¥30,360
Description

Lymphocyte antigen 6 complex, locus G (Ly-6G), a 21-25 kD GPI-anchored protein, is expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Ly-6G transfected EL-4J cell line.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-F - Verified
IHC - Reported in the literature, not verified in house
IHC-P, SB - Community verified
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C15. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A815. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.416.

Additional reported applications (for the relevant formats) include: immunohistochemistry9 of frozen sections10 and paraffin-embedded sections11, depletion4, 12-14, and spatial biology (IBEX)20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).

Additional Product Notes

This product has been verified for IHC-P (Immunohistochemistry - formalin-fixed paraffin-embedded tissues) on the NanoString GeoMx® Digital Spatial Profiler. The GeoMx® enables researchers to perform spatial analysis of protein and RNA targets in FFPE and fresh frozen human and mouse samples. For more information about our spatial biology products and the GeoMx® platform, please visit our spatial biology page.

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
  2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
  3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
  4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
  5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
  6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
  7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
  8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
  9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
  10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
  11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
  12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
  13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
  14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
  15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
  17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
  19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
  20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Kobayashi A, et al. 2021. Front Immunol. 12:650856. PubMed
  2. Liao X, et al. 2022. Front Immunol. 12:768813. PubMed
  3. Paterson MJ, et al. 2020. PLoS Pathog. 16:e1008733. PubMed
  4. Bruce DW, et al. 2021. Blood Adv. 5:4578. PubMed
  5. Poon C, et al. 2022. Focus (Am Psychiatr Publ). 20:100. PubMed
  6. Lalazar G, et al. 2016. Am J Physiol Gastrointest Liver Physiol. 311: G377 - G386. PubMed
  7. Hernández-Santana YE, et al. 2020. Life Sci Alliance. 3:00. PubMed
  8. Davies M, et al. 2017. PLoS Pathogens. 13(6):e1006435. PubMed
  9. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  10. Shen S, et al. 2018. Front Immunol. 1.06875. PubMed
  11. Guiducci C, et al. 2010. J Exp Med. 207:2931. PubMed
  12. Ringgaard L, et al. 2020. Sci Adv. 6:. PubMed
  13. Qu M, et al. 2022. Cell Death Discov. 8:375. PubMed
  14. Pilling D, et al. 2022. Respir Res. 23:215. PubMed
  15. Ho TY, et al. 2021. Mol Ther Oncolytics. 22:85. PubMed
  16. Reglero-Real N, et al. 2021. Immunity. :. PubMed
  17. Yago T, et al. 2015. J Exp Med. 212: 1267 - 1281. PubMed
  18. Choudhury SR, et al. 2020. Cell. 178(5):1205-1221.e17.. PubMed
  19. Mazor R, et al. 2018. Proc Natl Acad Sci U S A. 115:E733. PubMed
  20. Kapellos TS, et al. 2019. FASEB J. 33:6154. PubMed
  21. Bhatt K, et al. 2018. mSphere. 3:e00352. PubMed
  22. Burrello C, et al. 2018. Front Med (Lausanne). 5:21. PubMed
  23. Wang B et al. 2018. Cell stem cell. 22(2):206-220 . PubMed
  24. Elshal M, et al. 2022. Inflammopharmacology. :. PubMed
  25. Her Z, et al. 2015. EMBO Mol Med. 7:24. PubMed
  26. Simon N, et al. 2019. JCI Insight. 4:. PubMed
  27. Boeckel SRV, et al. 2019. Sci Rep. 9:7356. PubMed
  28. Merz SF, et al. 2019. Nat Commun. 10:2312. PubMed
  29. Ajona D, et al. 2017. Cancer Discov. 0.773611111. PubMed
  30. Goel S, et al. 2017. Nature. 548:471. PubMed
  31. Rehm SRT, et al. 2019. Sci Rep. 9:9925. PubMed
  32. Arnold IC, et al. 2018. J Exp Med. 215:2055. PubMed
  33. Whyte W, et al. 2022. Nat Commun. 13:4496. PubMed
  34. Han J, et al. 2022. FEBS J. 289:417. PubMed
  35. Cheng WJ, et al. 2021. Front Pharmacol. 12:762829. PubMed
  36. Karhadkar TR, et al. 2021. J Pharmacol Exp Ther. 376:106. PubMed
  37. Rogic A, et al. 2021. Nat Commun. 12:6889. PubMed
  38. Yao W, et al. 2019. Nature. 568:410. PubMed
  39. Meng L, et al. 2021. Front Oncol. 11:691705. PubMed
  40. Kleinholz CL, et al. 2021. Sci Rep. 11:15071. PubMed
  41. Scott NR, et al. 2020. J Clin Invest. 130:3098. PubMed
  42. Stefanescu C, et al. 2021. Front Oncol. 11:765151. PubMed
  43. Wang Y, et al. 2021. Cancer Cell. 39:1375. PubMed
  44. Juttukonda LJ, et al. 2017. Cell Host Microbe. 22:531. PubMed
  45. Verma M, et al. 2018. Brain Behav Immun. 69:223. PubMed
  46. Düsedau HP, et al. 2019. Glia. 67:193. PubMed
  47. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  48. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  49. Wang Y, et al. 2019. Cell. 179:1144. PubMed
  50. McLeod RL, et al. 2018. Oncotarget. 9:34459. PubMed
  51. Qu S, et al. 2018. Int J Cancer. 8:6685. PubMed
  52. Nakamizo S,et al. 2017. Sci Rep. . 10.1038/s41598-017-14292-1. PubMed
  53. O'Dea KP, et al. 2020. J Extracell Vesicles. 9:1706708. PubMed
  54. Hilligan KL, et al. 2020. Nat Commun. 11:5637. PubMed
  55. Suzuki Y, et al. 2021. FEBS Open Bio. 11:2619. PubMed
  56. Yan J, et al. 2020. Cancer Immunol Res. 8:356. PubMed
  57. Chen L, et al. 2020. Front Immunol. 11:584458. PubMed
  58. Andrade E, et al. 2013. J Immunol. 191:4759. PubMed
  59. Ng L, et al. 2011. J Invest Dermatol. 131:2058. PubMed
  60. Vallelian F, et al. 2018. Pharmacol Res Perspect. 15:5422. PubMed
  61. Nolin JD, et al. 2017. JCI Insight. 2:e94929. PubMed
  62. Silvestre-Roig C, et al. 2019. Nature. 569:236. PubMed
  63. Guiducci E, et al. 2018. Front Immunol. 1.467361111. PubMed
  64. Singh PP, et al. 2021. Ocul Surf. 21:271. PubMed
  65. Louwe MC, et al. 2020. JACC Basic Transl Sci. 1.048611111. PubMed
  66. Karhadkar TR, et al. 2021. PLoS One. 16:e0245924. PubMed
  67. Ilyas G, et al. 2015. J Hepatol. Available online 29 August 2015. PubMed
  68. Seelige R, et al. 2018. Sci Rep. 8:13670. PubMed
  69. Yang SH, et al. 2017. Front Immunol. 8:1192. PubMed
  70. Gu H, et al. 2018. Aging (Albany NY). 1.525694444. PubMed
  71. Stacey MA, et al. 2017. J Clin Invest. 127:1463. PubMed
  72. Chudnovskiy A et al. 2016. Cell. 167(2):444-456 . PubMed
  73. Perdomo J, et al. 2019. Nat Commun. 10:1322. PubMed
  74. Bence Daniel et al. 2018. Immunity. 49(4):615-626 . PubMed
  75. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  76. Mrdjen D et al. 2018. Immunity. 48(2):380-395 . PubMed
  77. Maybin JA, et al. 2018. Nat Commun. 9:295. PubMed
  78. Lai JF, et al. 2020. J Allergy Clin Immunol. 146:1406. PubMed
  79. Vito A, et al. 2021. Commun Biol. 4:859. PubMed
  80. Metz H, et al. 2016. Proc Natl Acad Sci U S A. 113: 8795 - 8800. PubMed
  81. Okubo K, et al. 2021. Cell Reports. 35(7):109142. PubMed
  82. Danobeitia J, et al. 2017. PLoS One.. 10.1371/journal.pone.0183701. PubMed
  83. Meers GK, et al. 2018. PLoS One. 13:e0190846. PubMed
  84. Mottahedin A, et al. 2017. J Leukoc Biol. 101:297. PubMed
  85. Schmid AS, et al. 2018. Rheumatology (Oxford). 57:748. PubMed
  86. Abboud G, et al. 2018. Front Immunol. 9:1973. PubMed
  87. Ottone OK, et al. 2022. Front Immunol. 13:882407. PubMed
  88. Hu G, et al. 2021. Nat Commun. 12:773. PubMed
  89. Kroh A, et al. 2020. Gastroenterol Res Pract. 7347068:2020. PubMed
  90. McCartney-Francis N, et al. 2014. J Leukoc Biol. 96:917. PubMed
  91. Reeves R 2010. J Immunol. 185:4904. PubMed
  92. Peterson LW, et al. 2017. J Exp Med. 214:3171. PubMed
  93. Kapellos TS, et al. 2017. Mediators Inflamm. 2017:4315412. PubMed
  94. Tsubaki T, et al. 2018. Oncotarget. 9:11209. PubMed
  95. Borges TJ, et al. 2018. Nat Commun. 9:3482. PubMed
  96. Hoves S, et al. 2018. J Exp Med. 215:859. PubMed
  97. Vu LT, et al. 2019. J Extracell Vesicles. 8:1599680. PubMed
  98. Johnson SA, et al. 2021. Eur J Immunol. 51:3228. PubMed
  99. Poon C, et al. 2021. Theranostics. 11:1655. PubMed
  100. Lim CS, et al. 2020. Front Immunol. 11:1186. PubMed
  101. Yoon S, et al. 2020. Antioxidants (Basel). 10:. PubMed
  102. Otxoa–de–Amezaga A, et al. 2019. Acta Neuropathol. 137:321. PubMed
  103. Davies CL, et al. 2019. Front Immunol. 10:1048. PubMed
  104. Paharik AE, et al. 2017. Cell Host Microbe. 22:746. PubMed
  105. Burr AC, et al. 2021. J Inflamm Res. 14:4035. PubMed
  106. Zhao D, et al. 2020. Cancer Discov. 10:1374. PubMed
  107. Karhadkar TR, et al. 2020. bioRxiv. . PubMed
  108. Jung H, et al. 2019. Autophagy. 15:1990. PubMed
  109. Shevchenko MA, et al. 2018. J Immunol Res. 8:53. PubMed
  110. Chipashvili O, et al. 2022. STAR Protoc. 3:101167. PubMed
  111. González LA, et al. 2021. Front Immunol. 12:638917. PubMed
  112. Li J, et al. 2021. Front Immunol. 12:710406. PubMed
  113. Fino KK, et al. 2017. Sci Rep. 5.334722222. PubMed
  114. Ford J, et al. 2019. Front Immunol. 2.502083333. PubMed
  115. Mensurado S, et al. 2018. PLoS Biol. 16:e2004990. PubMed
  116. Jiao L, et al. 2021. J Pathol. 255:270. PubMed
  117. Liu A, et al. 2021. J Nanobiotechnology. 19:280. PubMed
  118. Goh W, et al. 2020. Cell Rep. 33:108285. PubMed
  119. Kim D, et al. 2019. Immune Netw. 19:e32. PubMed
  120. Otxoa–de–Amezaga A, et al. 2019. Stroke. 50:1548. PubMed
  121. Vasamsetti SB, et al. 2018. Immunity. 49:93. PubMed
  122. Ferrer-Font L, et al. 2020. Elife. 9:. PubMed
  123. Pedragosa J, et al. 2021. Exp Neurol. 346:113865. PubMed
  124. Sacramento L, et al. 2015. Infect Immun . 83: 4604 - 4616. PubMed
  125. Bennewitz MF, et al. 2020. Blood Adv. 0.351388889. PubMed
  126. Wilson ZS, et al. 2020. Sci Rep. 10:2142. PubMed
  127. Bianchi–Frias D, et al. 2019. Mol Cancer Res. 17:321. PubMed
  128. Akiel M, et al. 2017. Cancer Res. 77:4014. PubMed
  129. Roussey JA, et al. 2017. J Immunol. 199:3535. PubMed
  130. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  131. Liu J, et al. 2022. Stem Cell Res Ther. 13:247. PubMed
  132. Andersen MJ, et al. 2022. Elife. 11:. PubMed
  133. Qiu Z, et al. 2022. Cancer Discov. 12:502. PubMed
  134. Takeuchi Y, et al. 2021. Sci Rep. 11:18679. PubMed
  135. Stempel H, et al. 2016. J Biol Chem. 291: 9762-9775. PubMed
  136. Sumagin R, et al. 2010. J Immunol. 185:7057. PubMed
  137. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  138. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
  139. McArthur S, et al. 2020. J Clin Invest. 130:1156. PubMed
  140. Lin L, et al. 2018. J Invest Dermatol. 138:1032. PubMed
  141. Scutts SR, et al. 2018. Cell Rep. 25:1953. PubMed
  142. Bonnart C, et al. 2017. Parasite Immunol.. 10.1111/pim.12489. PubMed
  143. Ipseiz N, et al. 2020. EMBO J. 39:e103454. PubMed
  144. Dey P, et al. 2020. Cancer Discov. 10:608. PubMed
  145. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
  146. Cané S, et al. 2021. J Immunother Cancer. 9:. PubMed
  147. Udumula MP, et al. 2021. Mol Metab. 53:101272. PubMed
  148. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  149. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
  150. Carper MB, et al. 2019. Cell Rep. 29:1660. PubMed
  151. Deng M, et al. 2019. J Exp Med. 216:2838. PubMed
  152. Kao TI, et al. 2021. Br J Pharmacol. 178:4069. PubMed
  153. James BN, et al. 2021. J Allergy Clin Immunol. 147:1936. PubMed
  154. Hunt LC, et al. 2021. Cell Rep. 37:109971. PubMed
  155. Tilburg J, et al. 2020. J Thromb Haemost. 1.940277778. PubMed
  156. Prows DR, et al. 2020. American Journal of Physiology-Heart and Circulatory Physiology. 317(2):H405-H414.. PubMed
  157. Zhao Z, et al. 2019. J Immunol Res. 2019:9561350. PubMed
  158. Song M, et al. 2020. Nat Commun. 11:6298. PubMed
  159. Raccosta L, et al. 2013. J Exp Med. 210:1711. PubMed
  160. An Y et al. 2018. Cell reports. 25(3):702-714 . PubMed
  161. Kikuchi K, et al. 2018. J Immunol. 201:635. PubMed
  162. Luo J, et al. 2019. Clin Cancer Res. 25:808. PubMed
  163. Zhang M, et al. 2018. Front Immunol. 2.285416667. PubMed
  164. Leist SR, et al. 2019. PLoS One. 14:e0220126. PubMed
  165. Cain D, et al. 2011. PLoS One. 6:e19957. PubMed
  166. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
  167. Kang SH, et al. 2018. Oncoimmunology. 8:e1515057. PubMed
  168. Regan–Komito D, et al. 2017. Front Immunol. 1.459027778. PubMed
  169. Watanabe K, et al. 2017. PLoS Pathog.. 10.1371/journal.ppat.1006513. PubMed
RRID
AB_1089179 (BioLegend Cat. No. 127601)
AB_1089180 (BioLegend Cat. No. 127602)

Antigen Details

Structure
A 21-35 kD GPI-anchorded membrane protein
Distribution

Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.

Cell Type
Granulocytes, Macrophages, Monocytes
Biology Area
Immunology, Innate Immunity
Antigen References

Fleming TJ, et al. 1993. J. Immunol. 151:2399.

Gene ID
546644 View all products for this Gene ID
UniProt
View information about Ly-6G on UniProt.org

Related FAQs

If an antibody clone has been previously successfully used in IBEX in one fluorescent format, will other antibody formats work as well?

It’s likely that other fluorophore conjugates to the same antibody clone will also be compatible with IBEX using the same sample fixation procedure. Ultimately a directly conjugated antibody’s utility in fluorescent imaging and IBEX may be specific to the sample and microscope being used in the experiment. Some antibody clone conjugates may perform better than others due to performance differences in non-specific binding, fluorophore brightness, and other biochemical properties unique to that conjugate.

Will antibodies my lab is already using for fluorescent or chromogenic IHC work in IBEX?

Fundamentally, IBEX as a technique that works much in the same way as single antibody panels or single marker IF/IHC. If you’re already successfully using an antibody clone on a sample of interest, it is likely that clone will have utility in IBEX. It is expected some optimization and testing of different antibody fluorophore conjugates will be required to find a suitable format; however, legacy microscopy techniques like chromogenic IHC on fixed or frozen tissue is an excellent place to start looking for useful antibodies.

Are other fluorophores compatible with IBEX?

Over 18 fluorescent formats have been screened for use in IBEX, however, it is likely that other fluorophores are able to be rapidly bleached in IBEX. If a fluorophore format is already suitable for your imaging platform it can be tested for compatibility in IBEX.

The same antibody works in one tissue type but not another. What is happening?

Differences in tissue properties may impact both the ability of an antibody to bind its target specifically and impact the ability of a specific fluorophore conjugate to overcome the background fluorescent signal in a given tissue. Secondary stains, as well as testing multiple fluorescent conjugates of the same clone, may help to troubleshoot challenging targets or tissues. Using a reference control tissue may also give confidence in the specificity of your staining.

How can I be sure the staining I’m seeing in my tissue is real?

In general, best practices for validating an antibody in traditional chromogenic or fluorescent IHC are applicable to IBEX. Please reference the Nature Methods review on antibody based multiplexed imaging for resources on validating antibodies for IBEX.

Other Formats

View All Ly-6G Reagents Request Custom Conjugation
Description Clone Applications
Alexa Fluor® 594 anti-mouse Ly-6G 1A8 IHC-F,SB
Purified anti-mouse Ly-6G 1A8 FC,IHC-F,IHC-P,SB
Biotin anti-mouse Ly-6G 1A8 FC,IHC
FITC anti-mouse Ly-6G 1A8 FC
PE anti-mouse Ly-6G 1A8 FC
Alexa Fluor® 647 anti-mouse Ly-6G 1A8 FC,IHC-F,SB
Pacific Blue™ anti-mouse Ly-6G 1A8 FC
APC anti-mouse Ly-6G 1A8 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G 1A8 FC
PE/Cyanine7 anti-mouse Ly-6G 1A8 FC
Alexa Fluor® 700 anti-mouse Ly-6G 1A8 FC,IHC
APC/Cyanine7 anti-mouse Ly-6G 1A8 FC
Alexa Fluor® 488 anti-mouse Ly-6G 1A8 FC,IHC-F,SB
Brilliant Violet 421™ anti-mouse Ly-6G 1A8 FC,IHC-F
Brilliant Violet 570™ anti-mouse Ly-6G 1A8 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G 1A8 FC,Depletion,IHC
Brilliant Violet 510™ anti-mouse Ly-6G 1A8 FC
Purified anti-mouse Ly-6G (Maxpar® Ready) 1A8 FC,CyTOF®,WB
Brilliant Violet 650™ anti-mouse Ly-6G 1A8 FC
Brilliant Violet 711™ anti-mouse Ly-6G 1A8 FC
Brilliant Violet 605™ anti-mouse Ly-6G 1A8 FC
Brilliant Violet 785™ anti-mouse Ly-6G 1A8 FC
PE/Dazzle™ 594 anti-mouse Ly-6G 1A8 FC
APC/Fire™ 750 anti-mouse Ly-6G 1A8 FC
PerCP anti-mouse Ly-6G 1A8 FC
TotalSeq™-A0015 anti-mouse Ly-6G 1A8 PG
TotalSeq™-C0015 anti-mouse Ly-6G 1A8 PG
TotalSeq™-B0015 anti-mouse Ly-6G 1A8 PG
Spark Blue™ 550 anti-mouse Ly-6G 1A8 FC
Spark NIR™ 685 anti-mouse Ly-6G 1A8 FC
Spark YG™ 593 anti-mouse Ly-6G 1A8 FC
APC/Fire™ 810 anti-mouse Ly-6G Antibody 1A8 FC
PE/Cyanine5 anti-mouse Ly-6G 1A8 FC
PE/Fire™ 810 anti-mouse Ly-6G Antibody 1A8 FC
Spark UV™ 387 anti-mouse Ly-6G 1A8 FC
PE/Fire™ 640 anti-mouse Ly-6G 1A8 FC
Spark YG™ 570 anti-mouse Ly-6G 1A8 IHC-F,FC
Go To Top Version: 8    Revision Date: 03/04/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account